Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.

Saved in:
Bibliographic Details
Title: Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Authors: Loke P; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia; Monash Children's Hospital, Clayton, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia., Orsini F; Murdoch Children's Research Institute, Parkville, VIC, Australia., Lozinsky AC; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia., Gold M; Department of Paediatrics, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia; Women's and Children's Hospital Adelaide, North Adelaide, SA, Australia., O'Sullivan MD; Immunology Department, Perth Children's Hospital, Child and Adolescent Health Service, Nedlands, WA, Australia; Discipline of Paediatrics, Medical School, The University of Western Australia, Perth, WA, Australia; Telethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia., Quinn P; Department of Paediatrics, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia; Women's and Children's Hospital Adelaide, North Adelaide, SA, Australia., Lloyd M; Murdoch Children's Research Institute, Parkville, VIC, Australia; School of Public Health and Preventative Medicine, Monash University, Melbourne, VIC, Australia., Ashley SE; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia., Pitkin S; Murdoch Children's Research Institute, Parkville, VIC, Australia; Monash Children's Hospital, Clayton, VIC, Australia., Axelrad C; Murdoch Children's Research Institute, Parkville, VIC, Australia., Metcalfe JR; Immunology Department, Perth Children's Hospital, Child and Adolescent Health Service, Nedlands, WA, Australia; Telethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia., Su EL; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia., Tey D; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia., Robinson MN; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia., Allen KJ; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia., Prescott SL; Immunology Department, Perth Children's Hospital, Child and Adolescent Health Service, Nedlands, WA, Australia; Telethon Kids Institute, The University of Western Australia, Nedlands, WA, Australia; NOVA Institute for Health, Baltimore, MD, USA; Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, MD, USA., Galvin AD; School of Applied Psychology, Cork University Hospital, University College Cork, Cork, Ireland; Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University, Moscow, Russia., Tang MLK; Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Parkville, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia. Electronic address: mimi.tang@rch.org.au.
Corporate Authors: PPOIT-003 study group
Source: The Lancet. Child & adolescent health [Lancet Child Adolesc Health] 2022 Mar; Vol. 6 (3), pp. 171-184. Date of Electronic Publication: 2022 Feb 04.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101712925 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-4650 (Electronic) Linking ISSN: 23524642 NLM ISO Abbreviation: Lancet Child Adolesc Health Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-4650
DOI:10.1016/S2352-4642(22)00006-2